🔗 Share this article

As America continues making sweeping changes to its vaccine guidelines, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on coronavirus shots throughout the global health crisis and has zeroed in on possible deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities had intended to reveal major changes to the childhood immunization program in December, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of step with much of the world with little proof for improved outcomes. The announcement has been postponed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A Shift at the FDA

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending certain childhood shot schedules in the US to become more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Background

Høeg has little discernible background in pharmaceutical research, oversight or leadership, which has been typical for previous leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just focuses on the innovative therapies, but the generic drug division approves numerous generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these need to be managed,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major administrative component to the position, which manages over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” Woodcock said.

Response and Contentious Policies

In response to inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “questions are based on incorrect presumptions”.

“This background is consistent with the functions of her job,” the official explained, citing the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid medication authorization process that allegedly worried her preceding directors. “How are these medications being selected for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if problematic, history, some experts have noted. She published a research paper using unconfirmed public submissions to estimate the incidence of heart inflammation after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the current administration encompassed altering rules for novel immunizations and discontinuing “non-essential” immunizations, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has according to sources suggested preventing young men from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a extremely deceptive, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|